Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

VRC-HIVMAB091-00-AB

Generic Name: VRC-HIVMAB091-00-AB

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Phase 2

Active, not recruiting

Posted: 2023/08/18

Sponsor:ViiV Healthcare

ID:NCT05996471

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Phase 1

Completed

Posted: 2022/03/22

Sponsor:ViiV Healthcare

ID:NCT05291520

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

ViiV Healthcare's N6LS Broadly Neutralizing Antibody Shows Promise in HIV Long-Acting Treatment

2 months ago

Phase IIb EMBRACE study demonstrates N6LS (VH109), administered every four months with monthly cabotegravir, successfully maintained viral suppression in 96% of participants receiving intravenous treatment.

Lenacapavir and Broadly Neutralizing Antibodies Show Promise as Twice-Yearly HIV Treatment

2 months ago

Phase II trial results demonstrate that lenacapavir combined with two broadly neutralizing antibodies (teropavimab and zinlirvimab) maintained viral suppression in 96% of participants over 26 weeks, comparable to daily oral regimens.

ViiV Healthcare Showcases Long-Acting HIV Innovations and Pipeline Advances at CROI 2025

3 months ago

Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention.

CROI 2025 to Showcase Breakthrough Research in HIV, COVID-19, and Viral Infections

3 months ago

The Conference on Retroviruses and Opportunistic Infections (CROI) 2025 will convene in San Francisco from March 9-12, featuring cutting-edge research on HIV cure strategies, COVID-19 variants, and viral infections.

Merck's Doravirine/Islatravir Combo Shows Promise in Phase 3 HIV-1 Trials

5 months ago

Merck's doravirine/islatravir (DOR/ISL) regimen demonstrated non-inferiority compared to current antiretroviral therapies in Phase 3 trials for HIV-1.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy